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Allogeneic stem cell transplantation for patients with acute myeloid leukemia (AML) and myelodysplastic
syndromes (MDS) has been performed primarily with an HLA-matched donor. Outcomes of haploidentical
transplantation have recently improved, and a comparison between donor sources in a uniform cohort of
patients has not been performed. We evaluated outcomes of 227 patients with AML/MDS treated with
melphalan-based conditioning. Donors were matched related (MRD) (n ¼ 87, 38%), matched unrelated (MUD)
(n ¼ 108, 48%), or haploidentical (n ¼ 32, 14%). No signiﬁcant differences were found between haploidentical
and MUD transplantation outcomes; however, there was a trend for improved outcomes in the MRD group,
with 3-year progression-free survival for patients in remission of 57%, 45%, and 41% for MRD, MUD, and
haploidentical recipients, respectively (P ¼ .417). Recovery of T cell subsets was similar for all groups. These
results suggest that haploidentical donors can safely extend transplantation for AML/MDS patients without an
HLA-matched donor. Prospective studies comparing haploidentical and MUD transplantation are warranted.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Hematopoietic stem cell transplantation (HSCT) is an
effective treatment for patients with acute myeloid leukemia
(AML) andmyelodysplastic syndromes (MDS) [1,2]. Reduced-
intensity conditioning regimens emerged in response to a
need to decrease transplantation-related toxicity and allow
transplantation of older patients or those with signiﬁcant
comorbidities [3,4]. Our group developed a ﬂudarabine-
melphalan (FM)ebased conditioning regimen [5-7]. Severaldgments on page 1981.
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ty for Blood and Marrow Transplantation.studies reported outcomes with FM conditioning for
HLA-matched related (MRD) and unrelated donor (MUD)
transplantations [8-13]. A modiﬁed version of this
regimen (including thiotepa) was used for haploidentical
transplantations (HaploSCT), initially with a T celledepleted
graft [14], and then with a T cellereplete graft and post-
transplantation cyclophosphamide (PTCy), tacrolimus,
and mycophenolate mofetil (MMF) for graft-versus-host-
disease (GVHD) prevention, as this latter strategy was
associated with lower nonrelapse mortality (NRM) with
nonmyeloablative conditioning [15,16]. We previously
compared these 2 strategies and showed that T cellereplete
HaploSCT was associated with better immunologic recon-
stitution, lower treatment-related mortality, and improved
outcomes, when comparedwith Tcelledepleted HaploSCT in
adult recipients [17].
Table 1
Demographics for All Patients
Measure All Patients (N ¼ 227) By Donor Type
MRD (n ¼ 87) MUD (n ¼ 108) Haplo (n ¼ 32) P Value
Age at HSCT, median (range), yr 60 (20-76) 60 (24-76) 62 (21-76) 52 (20-67) <.001*
Gender, n (%)
Male 128 (56) 52 (60) 60 (56) 16 (50) .610y
Female 99 (44) 35 (40) 48 (44) 16 (50)
HCT-CI total scores
Median (range) 3 (0-12) 3 (0-12) 3 (0-9) 1.5 (0-5) <.001*
HPC, n (%)
Peripheral blood 143 (63) 84 (97) 58 (54) 1 (3) <.001y
Bone marrow 84 (37) 3 (3) 50 (46) 31 (97)
Diagnosis, n (%)
AML, MDS/AML 151 (67) 58 (67) 71 (66) 22 (69) .994y
MDS 33 (15) 12 (14) 17 (16) 4 (13)
Secondary 43 (19) 17 (20) 20 (19) 6 (19)
Disease status, n (%)
CR 70 (31) 25 (29) 26 (24) 19 (59) <.001y
No CR 157 (69) 62 (71) 82 (76) 13 (41)
Cytogenetic risk, n (%)
n 220 83 106 31
Good 22 (10) 7 (8) 11 (10) 4 (13) .663y
Intermediate 110 (50) 38 (46) 55 (52) 17 (55)
Poor 88 (40) 38 (46) 40 (38) 10 (32)
HCT-CI indicates hematopoietic cell transplantation comorbidity index; HPC, hematopoietic progenitor cells; CR, complete remission.
* Kruskal-Wallis test.
y Fisher’s exact test.
A. Di Stasi et al. / Biol Blood Marrow Transplant 20 (2014) 1975e19811976Here, we compared outcomes for AML/MDS patients
treated with FM-based conditioning at our institution who
received either a haploidentical or a fully HLA-matched
related and unrelated donor transplants, and we evaluated
immunologic reconstitution in all 3 groups.MATERIALS AND METHODS
Patients
All 227 patients with AML/MDS who received an allograft using FM
conditioning between January 2005 and September 2012 were included in
this study. Eighty-seven patients (38%) received an MRD transplant, 108
(48%) received a 10/10 MUD transplant, and 32 (14%) received a hap-
loidentical transplant. All patients provided written informed consent, and
the University of Texas MD Anderson Cancer Center institutional review
board approved this retrospective analysis. Complete remission was deﬁned
as less than 5 percent bone marrow blasts with neutrophils 1 109/L and
platelets 100  109/L. Cytogenetic risk was classiﬁed according to the
SWOG risk category [16].Conditioning Regimen
All patients received ﬂudarabine (120 to 160 mg/m2 in 4 daily doses)
and melphalan 140 mg/m2 (n ¼ 190, 84%) or 100 mg/m2 (n ¼ 37, 16%) as a
single dose. Thiotepa 5 to 10 mg/kg was added for haploidentical trans-
plantation patients to enhance engraftment (n ¼ 32). Older patients and
those with major comorbidities received reduced doses of melphalan or
thiotepa. GVHD prophylaxis for matched transplantations consisted of
tacrolimus and mini-methotrexate  antithymocyte globulin (ATG)
added for MUD transplantation only [9] and PTCy 50 mg/kg on days þ3
and þ4, tacrolimus, and MMF for haploidentical transplantations [15].
Tacrolimus was started on day -2 for MRD and þ5 for haploidentical (to
maximize allo-activation, after performing allodepletion with PTCy, in an
immune-suppressiveefree environment) and MUD transplantations, and
discontinued after 6 months if there were no evidence of GVHD. MMF was
discontinued at day 100, unless otherwise indicated. All patients received
granulocyte colonyestimulating factor starting on day þ5 or þ7,
according with the clinical protocol, and standard antimicrobial pro-
phylaxis with ﬂuconazole or voriconazole, pentamidine or trimethoprim-
sulfamethoxazole, and valacyclovir for fungal, pneumocystis jiroveci, and
herpes simplex, respectively.
Hematopoietic progenitor cells were obtained from the bone marrow or
granulocyte colonyestimulating factor emobilized peripheral blood pro-
genitor cells collected by apheresis. All donors provided written informed
consent. Hematopoietic stem cells procured from unrelated donors were
obtained through the National Marrow Donor Program.Immunologic Reconstitution Studies
We performed lymphocyte reconstitution on available samples from
MRD, MUD, and haploidentical transplant recipients between days þ30
andþ365 after transplantation. The median number of samples analyzed by
group per each time point was 14 for haploidentical, 17 for MUD, and 5 for
MRD. The antibodies used were CD19-PE, CD8-APC, CD-3PECy7, CD4-PerCP-
Cy5.5, CD56-V450, and CD45-V500 (BD Biosciences, San Jose, CA). At least
10,000 live events in each sample were acquired. Data were analyzed by
using FCS Express software (De Novo Software, Los Angeles, CA). The per-
centage of donor chimerism was determined by PCR-based microsatellite
polymorphism analysis.
Statistical Analysis
Descriptive statistics are presented for all patients and donor types.
Categorical measures were assessed using Fisher exact test, whereas
continuous measures were assessed by the Kruskal-Wallis test [18]. NRM,
relapse, and GVHD were assessed by the cumulative incidence function
using the competing risks method. The competing risk included for NRM
was relapse, whereas the competing risk included for relapse was death. For
GVHD, the competing risks were relapse and death. The Kaplan-Meier
method was used to estimate overall survival (OS) and progression-free
survival (PFS) [19]. Differences between groups for the cumulative inci-
dence measures were determined using Gray’s test [20], whereas the
log-rank test was used to assess group differences for OS and PFS. Cox
proportional hazards regression models were ﬁt to evaluate prognostic
effects of demographic and clinical measures of interest on PFS [21]. All
statistical analyses were performed using SAS 9.3 for Windows (SAS Insti-
tute Inc., Cary, NC).
RESULTS
Transplantation Outcomes Based on Different Donor
Types
Demographics and characteristics of all treated patients
(n ¼ 227) are presented in Table 1, and characteristics for
patients in remission (n ¼ 70) before transplantation are
shown in Table 2. A statistically signiﬁcant difference
between donor types was observed for age, source of stem
cells, and hematopoietic cell transplantationespeciﬁc co-
morbidity index [22]. Considering that a signiﬁcantly higher
proportion of patients were in remission in the HaploSCT
group compared with in the matched groups, we analyzed
outcomes for patients in remission in addition to outcomes
of all treated patients.
Table 2
Demographics for Patients in Remission before Transplantation
Measure All Patients (n ¼ 70) By Donor Type
MRD (n ¼ 25) MUD (n ¼ 26) Haplo (n ¼ 19) P Value
Age at HSCT, yr
Median (range) 57 (22-71) 59 (25-71) 62 (24-70) 55 (22-67) .048*
Gender, n (%)
Male 36 (51) 15 (60) 11 (42) 10 (53) .452y
Female 34 (49) 10 (40) 15 (58) 9 (47)
HCT-CI total scores
Median (range) 2 (0-9) 3 (0-6) 3 (0-9) 0 (0-4) .002*
HPC, n (%)
Peripheral blood 40 (57) 23 (92) 16 (62) 1 (5) <.001y
Bone marrow 30 (43) 2 (8) 10 (38) 18 (95)
Diagnosis, n (%)
AML, MDS/AML 58 (83) 22 (88) 21 (81) 15 (79) .879y
MDS 6 (9) 1 (4) 3 (12) 2 (11)
Secondary 6 (9) 2 (8) 2 (8) 2 (11)
Disease status, n (%)
CR NA NA NA NA NA
No CR NA NA NA NA
Cytogenetic risk, n (%)
n 67 23 25 19
Good 6 (9) 1 (4) 4 (16) 1 (5) .216y
Intermediate 40 (60) 11 (48) 16 (64) 13 (68)
Poor 21 (31) 11 (48) 5 (20) 5 (26)
NA indicates not available.
* Kruskal-Wallis test.
y Fisher’s exact test.
A. Di Stasi et al. / Biol Blood Marrow Transplant 20 (2014) 1975e1981 1977Neutrophil engraftment occurred in 99%, 96%, and 97% of
MRD, MUD, and haploidentical patients, respectively, in the
entire cohort, whereas all patients in remission engrafted
with 100% donor cells. The great majority of patients in all
groups experienced full donor chimerism at day 30 after
transplantation (99%, 97% and 100%, respectively), and this
was sustained at day 100 after transplantation. The median
time to neutrophil recovery for HaploSCT recipients was
18 days (range, 8 to 21), longer than for MRD recipients with
a median of 13 days (range, 10 to 22) and MUD recipients
with a median of 12 days (range,10 to 27) (P< .001), whereas
platelet engraftment was 25 days (range, 18 to 46) for Hap-
loSCT,14 days (range,10 to 45) forMUD, and 16 days (range, 9
to 42) for MRD transplant recipients (P < .001). These dif-
ferences were related to the use of bonemarrow stem cells in
the HaploSCT group (Table 1).
Clinical outcomes were similar between the 3 donor
groups for all patients and for those in remission. PFS for all
patients with an MRD, MUD, and haploidentical donor, at 1
and 3 years after transplantationwas 52%, 42%, 43%, and 36%,
27%, 30% (P ¼ .120), and lower for patients not in remission;
42%, 30%, 10% and 27%, 21%, 10%, respectively (P ¼ .105).
For patients in remission, PFS for the MRD, MUD, and
haploidentical groups, at 1 and 3 years after transplantation
was 80%, 76%, and 64% and 57%, 45%, and 41%, respectively
(P ¼ .417) (Table 3, Figure 1A,B). We also compared outcomes
for patients in remission between the haploidentical and the
matched transplantation group combined (Supplemental
Figure S1). The 1 and 3-year PFS were 78% and 51% in the
matched group and 64% and 41% in the haploidentical group
(P ¼ .316), whereas OS at 1 and 3 years was 82% and 56%,
respectively, in the matched group and 77% and 66%, respec-
tively, in the haploidentical group (P ¼ .646). A multivariable
analysiswas also performed for PFS for patients in remission at
transplantation to determine prognostic effects of speciﬁc
measures of interest, including age at transplantation, disease
risk at diagnosis, melphalan dose, and donor type. None of
these factorswere signiﬁcantlyassociatedwithPFS (Figure1C).The incidence of GVHD was also similar between these
groups. For patient in remission, the 100-day cumulative inci-
dence of grades 2 to 4 acute GVHD was 24%, 19%, and 26%,
whereas the cumulative incidence of grades 3 and 4 acute
GVHD was 4%, 4%, and 0% for the MRD, MUD, and hap-
loidentical groups, respectively (P ¼ .685). The cumulative
incidence of chronic GVHD at 3 years after transplantation,
limited and extensive, was 46%, 42%, and 24% (P ¼ .518), and
extensive only was 29%, 23%, and 17% (P¼ .919) for MRD, MUD
haploidentical transplant recipients, respectively. NRM for pa-
tients in remission at day 100 was 0%, 4%, and 5% and at 1 year,
NRM was 8%, 8%, and 18% for MRD, MUD, and haploidentical
transplant recipients, respectively (P ¼ .486) (Table 3).
The incidence of viral reactivation for all 3 groups is
presented in Table 3. There was a trend towards higher
incidence of cytomegalovirus reactivation in the hap-
loidentical group (71% versus 48% for MRD and 54% for MUD
groups), whereas there was no Epstein-Barr virus reac-
tivation or post-transplantation lymphoproliferative disor-
der was observed in any of the 3 groups.
Immunologic Reconstitution
We compared recovery of lymphocyte subsets for pa-
tients who received a MRD and MUD and haploidentical
transplant between days þ30 and þ365 after trans-
plantation. A detailed representation of immune reconsti-
tution of T cell subsets for the 3 donor groups is reported in
Figure 2. Regardless of donor type, all patients approached
normal CD3þ counts at approximately day 180 after trans-
plantation, with a subsequent steep increase from day 270 to
day 365. Median absolute CD3þ count per mL at day 30 was
448 for MRD, 111 for MUD, and 71 for haploidentical re-
cipients (P ¼ .047), whereas at day 90, it was 252, 365, and
273, at day 180 it was 606, 497, and 601, and at day 365 it was
1221, 853, and 1576, respectively (P ¼ not signiﬁcant).
CD3þCD8þ cell counts predominated at all time points. No
other signiﬁcant differences in reconstitution of CD3þ/CD4þ
were found between samples of MRD, MUD, and
Table 3
Transplantation Outcomes for All Patients
Measure All patients (N ¼ 227) By Donor Type
MRD (n ¼ 87) MUD (n ¼ 108) Haplo (n ¼ 32) P Value
Day 30 chimerism
Donor engraftment
n 216 87 98 31
n (%) 210 (97) 86 (99) 94 (96) 30 (97) .441*
100% donor
n 208 85 93 30
n (%) 204 (98) 84 (99) 90 (97) 30 (100) .798*
CMV reactivation
n 224 87 106 31
n (%) 121 (54) 42 (48) 57 (54) 22 (71) .098*
EBV reactivation 0 0 0 0 -
CI aGVHD 2-4, d 100, % 30 31 29 29 .709y
CI aGVHD 3-4, d 100, % 7 11 6 0 .044y
CI cGVHD (extþlim), yr 3, % 34 43 30 19 .094y
CI cGVHD (ext), yr 3, % 24 31 21 11 .125y
Follow-up survivors
Median (range), mo 31 (.8-85.4) 45 (6.4-78.8) 40 (.8-85.4) 13 (1.6-31.2) <.001z
CI relapse (%) .750y
Day 100 8 7 8 10
Year 1 26 28 23 33
CI NRM (%) .099y
Day 100 18 10 26 13
Year 1 27 20 35 24
PFS (%) .120x
Day 100 74 83 65 78
Year 1 46 52 42 43
Year 3 31 36 27 30
Median (95% conﬁdence interval), d 284 (215-404) 411 (237-757) 238 (160-386) 276 (173-NE)
10/10 10/10 5/10
CMV indicates cytomegalovirus; EBV, Epstein-Barr virus; CI, cumulative incidence; a, acute; c, chronic; ext, extensive; lim, limited; NE, not estimable.
* Fisher’s exact test.
y Gray’s test.
z Kruskal-Wallis test.
x Log-rank test.
A. Di Stasi et al. / Biol Blood Marrow Transplant 20 (2014) 1975e19811978haploidentical transplantation patients. Natural killer (NK)
cell (CD3CD56þ) reconstitution was similar between the
matched and haploidentical groups at days 90, 180, and 270.
Matched transplantations had a signiﬁcantly higher median
absolute NK cell numbers very early after transplantation
compared with haploidentical patients (day 30:197, 221, and
47/mL, respectively; P ¼ .019), whereas haploidentical
recipients had the highest median number of NK cells at day
365 (48, 201, and 387/mL, respectively; P ¼ .002). The median
absolute number of CD20þ cells (B cells)/mL at day 30 were
low in all patients and had similar reconstitution in all 3
groups thereafter (Figure 2).
DISCUSSION
In the present study, we analyzed outcomes for a uniform
cohort of AML/MDS patients treated during the same period
of time with the same conditioning regimen, and we
compared outcomes for different donor types including
matched related, unrelated, and haploidentical donors. We
found that outcomes for patients who underwent trans-
plantation with a haploidentical donor performed with a T
cellereplete graft and PTCy, tacrolimus, and MMF for GVHD
prophylaxis were comparable to those for patients who
underwent matched transplantations treated with conven-
tional GVHD prophylaxis. These ﬁndings were noted not only
for all patients but also for those in remission, as more
patients in the matched transplantation group were not in
remission at transplantation.
Overall, there was a nonsigniﬁcant trend for improved
outcomes with MRD transplantations, whereas the survivalcurves were superimposable for haploidentical and MUD
transplantations. As previously reported by others and us,
chronic GVHD was lower in the HaploSCT group, likely
owing to the use of PTCy, consistent with results from
another recent study [23]. Compared with the recent study
from Bashey et al., here we report on results from a ho-
mogenous cohort of patients with the same diagnosis and
conditioning regimen. In addition, our analysis showed that
haploidentical transplantation was not associated with a
higher relapse rate, as previously suggested [24], when we
compared transplantation outcomes with matched trans-
plantations for patients with AML/MDS treated with the
same conditioning regimen. Burroughs et al. retrospec-
tively compared outcomes for patients with Hodgkin’s
disease treated with nonmyeloablative conditioning with
haploidentical, matched sibling, and unrelated donor
transplantations [25]. In their study, haploidentical re-
cipients experienced lower treatment-related mortality as
well as a signiﬁcant decreased risk in relapse compared
with the HLA-matched related and unrelated recipients,
with outcomes at least as good as matched transplantations
[25]. Taken together, these 2 retrospective studies
(including ours), suggest that haploidentical trans-
plantations may now offer similar outcomes to matched
transplantations.
Regarding the role of type and conditioning intensity
and outcomes, results from retrospective studies suggest
that survival after administration of reduced-intensity con-
ditioning for AML/MDS is comparable to that after
myeloablative regimens, and whether the drug used for
Figure 1. Transplantation outcomes for recipients of haploidentical, matched related, and 10/10 HLAematched unrelated donor transplantations. (A) All treated
patients and (B) patients in remission at transplantation. Progression-free survival (PFS), overall survival (OS), and cumulative incidence of nonrelapse mortality
(NRM) are shown. (C) Multivariable analysis for PFS for patients in remission before transplantation, in relation to age, cytogenetic risk (SWOG), melphalan dose,
donor type (matched versus haploidentical), and hematopoietic stem cell comorbidity index.
A. Di Stasi et al. / Biol Blood Marrow Transplant 20 (2014) 1975e1981 1979conditioning chemotherapy (for example busulfan versus
melphalan) might affect outcome is currently unknown.
Other studies reported comparable results for haploiden-
tical transplantations using busulfan-based conditioning,
suggesting that both melphalan-based or busulfan-based
conditioning may be adequate if a more intense condition-
ing regimen (rather than nonmyeloablative) is considered
[26].
Immune-suppression prophylaxis may diminish the
graft-versus-leukemia effect, although it can signiﬁcantly
reduce the mortality risk from GVHD. In our study, ATG was
added to tacrolimus and mini-methotrexate as GVHD pro-
phylaxis for MUD transplantations only. Here, we used a
lower dose of rabbit ATG that is unlikely to signiﬁcantly in-
ﬂuence the outcomes, as a large Center for International
Blood and Marrow Transplant Research study showed that
only higher ATG doses (>7mg/kg) were associated with high
incidence of infections and relapse [27].
Immunologic reconstitution of lymphocyte subsets was
also similar between the 3 groups for all post-transplantation
time points analyzed, except on day 30, where we found thatMRD transplantations reconstituted earlier CD4þ and CD8þ
cells compared with the other 2 groups. Interestingly, the
use of PTCy in this setting did not appear to delay
immune recovery of T cell subsets in the haploidentical
transplantation group, which has been another concernwith
this form of GVHD prevention. Future studies will need to
investigate in depth the immune recovery between trans-
plantations with different donors and different forms of
GVDH prevention.
Limitations of this study are primarily related to the
relatively small number of patients and the retrospective
nature of this study. Patients in the haploidentical trans-
plantation group were younger, tended to have lower
hematopoietic cell transplantationespeciﬁc comorbidity
index scores than matched transplant recipients, and had
overall shorter median follow-up. Patients in the MRD
group appeared to experience better PFS compared with the
haploidentical and MUD groups. Because of a smaller sam-
ple size and the potential lack of power, a statistically sig-
niﬁcant difference was not detected. In addition, although
enough samples were available for the MUD and
Figure 2. Recovery of T cell subsets for recipients of haploidentical, matched sibling, and 10/10 HLAematched unrelated donor transplantations. Median number of T
lymphocyte subsets, B cells (CD20þ) and natural killer cells (CD3negCD56þ) are shown for each donor type (horizontal lines indicate reference values), and table
displays range value.
A. Di Stasi et al. / Biol Blood Marrow Transplant 20 (2014) 1975e19811980haploidentical groups, the relatively small sample size
available to evaluate immune reconstitution in the matched
related donor group could have impaired our ability to
detect other differences between this group and the other 2.
However, despite these limitations, our study is the ﬁrst
analysis that compares transplantation outcomes and im-
mune reconstitution for patients with AML/MDS in a uni-
form cohort, treated with the same conditioning regimen
during the same period of time. These results suggest that
patients with a transplantation indication may proceedsafely with transplantation using a haploidentical donor as
alternative to a matched donor.
In conclusion, our analysis found that outcomes of
patients with AML/MDS treated with transplants from
HLA-haploidentical donors are comparable at least with
outcomes of patients treated with matched unrelated donor
transplants. Prospective randomized trials are needed to
directly compare these 2 donor sources, as similar outcomes
may allow patients with more aggressive or advanced
disease to proceed faster to transplantation.
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